盐霉素钠
| 中文名称 | 盐霉素钠 |
|---|---|
| 中文同义词 | 盐霉素钠盐;盐霉素预混;盐霉素SV钠盐的五个半水合物;盐霉素 单钠盐 水合物;盐霉素溶液, 100PPM;沙利霉素钠;沙利诺马辛;盐霉素钠 |
| 英文名称 | Salinomycin |
| 英文同义词 | SALINOMYCIN SODIUM SALT 2.5-HYDRATE;SALINOMYCIN SV SODIUM SALT 2,5-HYDRATE;Salinomycin hydrate monosodium salt;Salinomycin sodium premix;Salinomycin, monosodium salt;salinomycin monosodium salt hydrate;Salinomycin-Natrium;(2R)-2-[(5S,6R)-6-[(2S,3S,4S,6R)-6-[(2S,5R,7S,9S,10S,12R,15R)-2-[(2R,5R,6S)-5-Ethyl-5-hydroxy-6-methyloxan-2-yl]-15-hydroxy-2,10,12-trimethyl-1,6,8-trioxadispiro[4.1.5.3]pentadec-13-en-9-yl]-3-hydroxy-4-methyl-5-oxooctan-2-yl]-5-methyloxan-2-yl]butanoic acid |
| CAS号 | 55721-31-8 |
| 分子式 | C42H71NaO12 |
| 分子量 | 791 |
| EINECS号 | 611-309-0 |
| 相关类别 | 驱虫保健剂;饲料添加剂;促生长;预防和治疗鸡的球虫病;抗球虫促长剂;畜禽促长剂;微生物代谢物;聚醚类抗生素;生长促进剂;化工原料;试剂盒-细胞分析试剂盒;Chiral Reagents;Organics;Antibiotics;BactericidalAntibiotics;Chemical Structure;OthersAlphabetic;Principle;S;SA - SM;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals |
| Mol文件 | 55721-31-8.mol |
| 结构式 |  |
盐霉素钠 性质
| 熔点 | 140-142° |
|---|---|
| 比旋光度 | D25 -37° (c = 1 in ethanol) |
| 储存条件 | APPROX 4°C |
| 溶解度 | 溶于二甲基亚砜。 |
| 颜色 | 白色 |
| Merck | 13,8415 |
| BRN | 4901827 |
| 稳定性 | DMSO中的溶液可在-20°下稳定储存3个月。 |
Wnt/β-catenin
Salinomycin (0.1-8 µM) inhibits the growth of HUVECs in a dose-dependent manner, accounting for 32.1 and 59.2% inhibition at 4 and 8 µM, respectively. HUVECs exposed to 2, 4 and 8 µM of Salinomycin for 48 h show a dose-dependent reduction in cell number and a change in cell morphology. Salinomycin (4 µM) treatment effectively inhibits HUVEC migration and invasion, and significantly disrupt the capillary-like tube formation of HUVECs. Salinomycin significantly suppresses the expression levels of phosphorylated (p)-FAK in a time- and dose-dependent manner in HUVECs. Salinomycin inhibits HUVEC angiogenesis by disturbing the VEGF-VEGFR2-AKT signaling axis. Combination of RSVL and Salinomycin synergistically inhibits the proliferation of TNBC (MDA-MB-231) cells. RSVL and Salinomycin effectively reduce wound healing, colony and tumorosphere forming capability in TNBC cells. Synergistic combination of RSVL and Salinomycin induces apoptosis in both culture conditions by significant upregulation of Bax with decreased Bcl-2 expression as comparison to untreated and alone drug treatments. Salinomycin (0, 2, 4, 8 and 16 μM) significantly inhibits the proliferation of A2780 and SK-OV-3 cell lines in a dose- and time-dependent manner, (IC 50 24h : 13.8 μM, IC 50 48h : 6.888 μM and IC 50 72h : 4.382 μM for A2780 cell lines), (IC 50 24h : 12.7 μM, IC 50 48h : 9.869 μM and IC 50 72h : 5.022 μM for SK-OV-3 cell lines). Salinomycin blocks the Wnt/β-catenin pathway in EOC cells. Salinomycin (2 μM) reduces cancer cell proliferation, inhibits STAT3 phosphorylation and P38 and β-catenin expressions, and suppresses epithelial-mesenchymal transition in colorectal cancer cells. Salinomycin (1-5 μM) inhibits cancer cell proliferation and STAT3 signaling in colorectal cancer cells. Furthermore, Salinomycin activates Akt (Ser 473) and down-regulates Hsp27 (Ser 82) phosphorylation in HT-29 and SW480. Salinomycin down-regulates hTERT and reduces telomerase activity when combined with telomerase inhibitor.
Salinomycin (5 and 10 mg/kg) significantly supresses the average tumor volume and tumor weight. Salinomycin hinders the U251 human glioma cell growth in vivo via inhibition of angiogenesis with involvement of AKT and FAK dephosphorylation. Salinomycin (0.5 mg/kg b.wt.) enhances the mean survival time of the tumor bearing Swiss albino mice.